Work

A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.lba5500

Authors: Joyce Liu, William Thomas Barry, Michael J. Birrer, Jung-min Lee, Ronald J. Buckanovich, Gini F. Fleming, Bj Rimel, Mary K. Buss, Sreenivasa R. Nattam, Jean Hurteau, Weixiu Luo, Philippa Quy, Elizabeth Obermayer, Christin Whalen, Hang Lee, Eric P. Winer, Elise C. Kohn, S. Percy Ivy, Ursula Matulonis

Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, National Institutes of Health, National Cancer Institute, University of Michigan, University of Chicago Medical Center, Cedars-Sinai Medical Center, Beth Israel Deaconess Medical Center, University of Chicago

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2240516173

Cites:

Cited by: 26

Related to: 10